Acute myeloid leukemia with t(11;12)(p15;q13) translocation: two cases report and literature review.
- VernacularTitle:伴t(11;12)(p15;q13)急性髓系白血病二例报告并文献复习
- Author:
Ben-fa GONG
1
;
Qi-hui LI
;
Wei LI
;
Ying WANG
;
Hui WEI
;
Jin-yu WANG
;
Xing-li ZHAO
;
Dong LIN
;
Cheng-wen LI
;
Xu-ping LIU
;
Ying-Chang MI
;
Jian-xiang WANG
Author Information
- Publication Type:Case Reports
- MeSH: Abnormal Karyotype; Adolescent; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 12; Humans; Leukemia, Myeloid, Acute; genetics; therapy; Male; Middle Aged; Prognosis; Translocation, Genetic
- From: Chinese Journal of Hematology 2013;34(10):830-833
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical and laboratory features of acute myeloid leukemia (AML) with t(11;12)(p15;q13) translocation.
METHODSTwo cases of AML with t(11;12)(p15;q13) translocation were reported and the related literatures were reviewed.
RESULTSThe diagnosis of AML-M3 was supported by morphological, cytochemical staining and electron microscope tests. A rare t(11;12)(p15;q13) translocation, but not classical t(15;17)(q22;q12) translocation and PML- RARα fusion gene, was detected in both cases. Both of the patients were refractory to differentiation induction therapy such as retinoic acid and arsenic trioxide.
CONCLUSIONAML is a group of heterogeneous disease derived from hematopoietic stem cell. Cytogenetic characteristic is important for diagnosis, prognosis stratification and therapy selection. Because of the heterogeneity of clinical and molecular features, it is unsuitable to classify AML with t(11;12)(p15;q13) as AML with recurrent cytogenetic aberration. This group of disease may benefit from allogeneic hematopoietic stem cell transplantation.
